Search
Cedazuridine
go.drugbank.com/drugs/DB15694ApprovedInvestigational[A215107, A215112, A215117, A215127, L14897] Cedazuridine was first reported in 2014,[A215107] and was subsequently approved by the FDA on July 7, 2020, in combination with [decitabine] for sale by
alpha-Tocopherol acetate
go.drugbank.com/drugs/DB14003ApprovedAlpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements. In particular, the RRR-alpha-tocopherol (or sometimes called the d-alpha-tocopherol stereoisomer) s...
Mixtures: O-Cal FA multivitaminValproic acid
go.drugbank.com/drugs/DB00313ApprovedInvestigationalIt first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects.
Nifurtimox
go.drugbank.com/drugs/DB11820ApprovedInvestigationalOn August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.
Romosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalRomosozumab was granted FDA approval on April 9,2019[L5921].
Deflazacort
go.drugbank.com/drugs/DB11921ApprovedIt is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.
Categories: Corticosteroid Hormone Receptor AgonistsPizotifen
go.drugbank.com/drugs/DB06153ApprovedSandomigran is available in a number of countries but is not approved by the FDA nor EMA.
Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin Receptor AntagonistsMethacholine
go.drugbank.com/drugs/DB06709Approved[A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]
Categories: Cholinergic Receptor AgonistGadoxetic acid
go.drugbank.com/drugs/DB08884ApprovedInvestigational[A263146] Gadoxetic acid, under the form gadoxetate disodium, is marketed by Bayer HealthCare Pharmaceuticals under the brand name EOVIST and FDA approved in 2008.[A263151]
Obinutuzumab
go.drugbank.com/drugs/DB08935ApprovedInvestigational[L54521] First approved by the FDA on February 26, 2016,[L54531] obinutuzumab is used to treat chronic lymphocytic leukemia, follicular lymphoma, and lupus nephritis.[L54521]